Aethlon Medical, Inc. (AEMD)

SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia. The study is a safety, feasibility, and dose-finding trial evaluating the company's Hemopurifier (HP) in patients with cancer not responding to anti-PD-1 therapy.

SAN DIEGO , Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 5,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrant.

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2026 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants James B. Frakes - CEO, CFO, Secretary & Director Steven P.

Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments.

SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2025, at 4:15 p.m. ET on Wednesday, August 13, 2025.

SAN DIEGO , July 15, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification. The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab", is being conducted to assess the Hemopurifier's safety, feasibility, and optimal dosing.

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2025 Earnings Conference Call June 26, 2025 4:30 PM ET Company Participants James B. Frakes - CEO, CFO, Secretary & Director Conference Call Participants Anthony V.

Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.

SAN DIEGO , June 20, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal fourth quarter ended March 31, 2025, at 4:15 p.m. ET on Thursday, June 26, 2025.

Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , June 18, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the second patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study).

Poster Presentation Reviews the Hemopurifier ® Affinity Resin's A bility to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO , June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 (https://www.keystonesymposia.org/conferences/conference-listing/meeting/program-highlights/F12026). Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19).

Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications SAN DIEGO , May 14, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication ( https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1 ) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (EVs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need.

Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology Results Support Further Evaluation of the Hemopurifier ®  as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys SAN DIEGO , March 10, 2025 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids.

Aethlon Medical invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Feb. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025.

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q3 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Jim Frakes – Chief Executive Officer Steven LaRosa – Chief Medical Officer Conference Call Participants Marla Marin – Zacks Anthony Vendetti – Maxim Group Operator Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2025 Earnings and Corporate Update Call. All participants will be in a listen-only mode.

Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments.